Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study

Zongbi Yi(Wuhan University), Binghe Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Fei Ma(Chinese Academy of Medical Sciences & Peking Union Medical College), Haili Qian(Chinese Academy of Medical Sciences & Peking Union Medical College), Binliang Liu(Central South University), Xiuwen Guan(Chinese Academy of Medical Sciences & Peking Union Medical College), Chunxiao Li(University of Cambridge), Lixi Li(Chinese Academy of Medical Sciences & Peking Union Medical College)
BMC Cancer
May 14, 2019
10.1186/s12885-019-5668-3
Cited by 33

Related Papers

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
|Annals of Oncology|2020|1.4k
Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021
|Annals of Oncology|2021|799
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724